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Cancer is one of the leading causes of death worldwide and the
numbers are increasing year on year. As cancer diagnosis and
treatment improves, however, more of these people will survive
for longer than ever before, making decisions over the quality of
life during and after treatment much more important [1].
Cancer chemotherapy: its effect and impact
Most cancer patients, especially those with advanced disease,
receive treatment with a cocktail of cytotoxic drugs, many of
which are associated with severe side effects, both in the
short and longer term. These lead to dose reductions and delays
in treatment and can even mean that treatment has to be
stopped early, limiting the use of otherwise very effective drug
regimens.1508 www.drugdiscoverytoday.com 1359-6446/06/$ - see front mattCancer chemotherapeutics such as oxaliplatin increase the
oxidative stress on cells. This is linked with a range of side effects
including an impact on the blood-forming cells in the bone
marrow, which increases the risk of infection [2,3]. Oxidative
stress may also have a role in the development of chemothera-
py-induced peripheral neuropathy [4] that impacts patients in the
long term, persisting in up to 35% of patients five or six years after
cessation of oxaliplatin-based treatment [5].
As an example, in colorectal cancer, the third most common
cancer-related cause of death in the developed world, commonly
used chemotherapeutic regimens include FOLFOX (folinic acid
[leucovorin], fluorouracil and oxaliplatin). FOLFOX is usually
dosed on alternate weeks. Because of the side effects, only around
half of patients can tolerate 8–12 cycles of treatment and many
cannot even cope with four cycles before the treatment has to be
modified because of the extent of side effects.
Quality of life is key for patients
According to Cancer Research UK, there were 14.1 million new
cases of cancer reported in 2012. This figure could increase to 23.6
million each year by 2030, an increase of 66% in low and medium
human development index (HDI) countries and 56% in high and
very high HDI countries [6]. Because diagnostics have become
more sensitive, physicians are able to treat cancer at a much earlier
stage, improving the chance of a positive outcome and long-term
survival.
This is especially true for the cancers that affect children and
young people. Overall, around two out of three people survive
cancer for at least five years after diagnosis [1]; this rises to around
4 in 5 in cases of childhood cancer [7]. Of the 12 million or so cancer
survivors in the US in 2012, at least 328,000 were diagnosed under
the age of 21 [7]. As people are living longer, quality of life,
particularly with respect to long-term and late effects of cancer
treatment, is becoming a key issue for both physicians and patients.
It will also be a concern for healthcare providers, in that as cancer
survivors age any unexpected long-term effects on organs such as
the heart, brain, kidneys and liver may become more apparent.
Because of this, the authorities are also taking note, with quality of
life becoming an important factor in pricing and reimbursement
discussions. As a response, pharmaceutical companies will have to
switch their focus away from chemotherapeutics that have aner  2014 Elsevier Ltd. All rights reserved. http://dx.doi.org/10.1016/j.drudis.2014.08.001
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alimpact on cancer in the short-term towards agents that provide
quality of life both now and many years in the future.
Taking a different approach
Drug development is a long and costly process; it can cost up to
$350 million to take a drug from concept to launch, and take well
over a decade. The figures are not quite as simple as that, however.
Taking into account the number of drugs that fail, companies
typically spend up to $6.3 billion getting a successful drug onto the
market.
The cancer market is a crowded and competitive one. At one end
of the market, there are many older but still effective drugs
available as lower cost generics, but that have drawbacks including
the high levels of side effects and the development of resistance. At
the other end, there are highly effective targeted therapeutics that
have relatively lower levels of side effects. These are generally
much more expensive, so treatment may not be affordable for
all patients or payors and are only relevant to smaller groups of
patients.
Rather than creating entirely new cancer chemotherapeutics,
companies can cut development costs, risk and timescales by
developing agents based on an already launched drug with a
known safety profile. By focusing on developing drugs that can
be used as an add-on to reduce the side effects of a range of
commonly used regimens, small biopharma companies can create
a niche market where the competition is not as fierce.
We are using this approach at PledPharma. Our lead product is
PledOx (calmangafodipir), and rather than acting as a chemother-
apeutic in its own right, we created it to work as a pretreatment
before chemotherapy to reduce the side effects. PledOx is based on
mangafodipir, a previously approved MRI contrast agent that has
been found to mimic manganese superoxide dismutase and so has
the potential to reduce oxidative stress on cells and it has been
demonstrated to have both protective and anticancer effects [3].
MRI contrast agents have to be very low toxicity and manga-
fodipir has been used safely on more than 200,000 patients.
However, they are designed for single administration. When used
repeatedly, mangafodipir turned out to release large amounts of
manganese, which can have toxic effects, particularly on the brain.
PledPharma’s drug developers have tailored mangafodipir by
replacing much of the manganese with calcium, creating calman-
gafodipir, and this appears to be both safer and more effective.
Even though there is an increased interest in repurposing and
improving older drugs, there can be issues with patent protection
and exclusivity. These modifications mean that we can also have
secure levels of IP protection in place.
In animal studies, PledOx reduced myelosuppression in mice
receiving oxaliplatin. Reducing the impact of chemotherapy on
white blood cells reduces the risk of life-threatening infections,
and suggests an additional role for the drug. The drug also in-
creased the efficacy of oxaliplatin against the tumours [8].Our initial focus is on reducing long-term peripheral neuropa-
thy in patients receiving FOLFOX for colorectal cancer, and phase
IIb clinical trials are under way. It also has potential in other
cancers and with other regimens.
One of the key issues will be persuading oncologists that these
agents will not reduce the efficacy of anticancer drugs, and perhaps
even persuading patients who may believe that the side effects are
an indication that the drug is working. While the anticancer effect
is not a current focus, it acts as a reassurance for physicians and for
patients that adding in another drug will not make treatment less
effective.
Looking at the way ahead
There is an enormous market potential for companies that are
looking to expand into combination therapies and different regi-
mens. Working in niche areas, such as add-ons to cancer treat-
ment regimens, is likely to be the way ahead, particularly for
smaller biopharma companies that do not have the budgets of big
pharma.
Companies working in new fields and niche areas have to ‘break
the ground’ compared with existing therapeutic areas. However,
there are more benefits than drawbacks, for example the opportu-
nity to beat the competition and create a new market. Moving
forward, the pharmaceutical industry also needs to see opportu-
nities in combination therapies based on older drugs, for example
packaging branded generics with complementary drugs such as
PledOx.
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